Pyrithiamine as a substrate for thiamine pyrophosphokinase

Area of Science:

• Biochemistry
• Enzymology
• Neuroscience

Background:

• Thiamine pyrophosphokinase (TPP) produces thiamine pyrophosphate (TPP), essential for preventing neurological and cardiovascular diseases.
• Thiamine deficiency causes Wernicke-Korsakoff Syndrome and wet beriberi.
• Pyrithiamine, a thiamine metabolism inhibitor, mimics Wernicke-Korsakoff Syndrome symptoms but its mechanism is unclear.

Purpose of the Study:

• To elucidate the mechanism by which pyrithiamine inhibits thiamine pyrophosphokinase.
• To understand how pyrithiamine interferes with cellular thiamine phosphoester homeostasis.

Main Methods:

• Kinetic assays coupled with mass spectrometry.
• X-ray crystallography of enzyme-reaction mixture equilibrium.

Main Results:

• Thiamine pyrophosphokinase forms pyrithiamine pyrophosphate when pyrithiamine is a substrate.
• Mass spectrometry confirmed the presence of pyrithiamine pyrophosphate.
• X-ray crystallography revealed pyrithiamine pyrophosphate bound in the enzyme's active site, showing the nucleoside triphosphate binding pocket.

Conclusions:

• Pyrithiamine inhibits thiamine pyrophosphokinase by acting as a substrate, forming pyrithiamine pyrophosphate.
• This study provides the first structural insights into the enzyme's active site and catalytic requirements.
• The findings clarify pyrithiamine's mechanism of action and its link to neurological symptoms.